Media Summary: Get a first look at the future of high-throughput, next-generation sequencing with AXELIOS 1. Powered by sequencing by ... 'Securing Cobalt-60 supply – An Update Direct from the Source' webinar hosted by the iia, 30th June 2026. This webinar provides ... Imugene Ltd managing director and CEO Leslie Chong talked with Proactive about the first complete response reported in the ...

Introducing The Act001 Inline Current - Detailed Analysis & Overview

Get a first look at the future of high-throughput, next-generation sequencing with AXELIOS 1. Powered by sequencing by ... 'Securing Cobalt-60 supply – An Update Direct from the Source' webinar hosted by the iia, 30th June 2026. This webinar provides ... Imugene Ltd managing director and CEO Leslie Chong talked with Proactive about the first complete response reported in the ... In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, Recent medical advances are revealing hidden clues about the underlying biology of pediatric cancers and are helping to rapidly ... Actuate Therapeutics' new mechanism-of-action animation easily explains how elraglusib, a novel GSK-3β inhibitor, is designed ...

In Episode 7 of Agilent's Dialogues in CDx, we turn our focus to recent advances in head and neck cancers, a field marked by ... Dr. Arrillaga is a neuro-oncologist at the Massachusetts General Hospital. She served as clinical director of the Pappas Center for ... ACT publishes phase 1/2 clinical trial data showing safety and signs of visual improvement of RPE cells for the treatment of ... When radiation therapy is recommended, patients will now have access to the recently installed TrueBeam linear accelerator at ...

Photo Gallery

Introducing the ACT001 Inline Current Sensor
Discover the AXELIOS 1 Next-Generation Sequencing Platform
ACT001 reduces neuroinflammation after traumatic brain injury
Securing Cobalt-60 supply – An Update Direct from the Source | WEBINAR RECORDING
Imugene azer-cel trial shows complete response
Revumenib plus IC in newly diagnosed NPM1-mutated AML: REVEAL-ND NPM1 trial-in-progress
Accelerating Discoveries: The Children's Brain Tumor Network
Actuate Therapeutics: targeting cancer on multiple fronts with elraglusib
Episode 7: PD-L1 Testing in Head & Neck Cancer - Current Practice and Clinical Impact
Phase II Trial in Glioblastoma with ONC201, a First in Class DRD2 Antagonist
Gilian Crowther, Director of Research talks about ArminLabs testing
ACT’s Phase 1/2 Clinical Trials Show Safety & Signs of Visual Improvement – Published in The Lancet
View Detailed Profile
Introducing the ACT001 Inline Current Sensor

Introducing the ACT001 Inline Current Sensor

We demonstrate the new

Discover the AXELIOS 1 Next-Generation Sequencing Platform

Discover the AXELIOS 1 Next-Generation Sequencing Platform

Get a first look at the future of high-throughput, next-generation sequencing with AXELIOS 1. Powered by sequencing by ...

ACT001 reduces neuroinflammation after traumatic brain injury

ACT001 reduces neuroinflammation after traumatic brain injury

Cai, et al. “

Securing Cobalt-60 supply – An Update Direct from the Source | WEBINAR RECORDING

Securing Cobalt-60 supply – An Update Direct from the Source | WEBINAR RECORDING

'Securing Cobalt-60 supply – An Update Direct from the Source' webinar hosted by the iia, 30th June 2026. This webinar provides ...

Imugene azer-cel trial shows complete response

Imugene azer-cel trial shows complete response

Imugene Ltd managing director and CEO Leslie Chong talked with Proactive about the first complete response reported in the ...

Revumenib plus IC in newly diagnosed NPM1-mutated AML: REVEAL-ND NPM1 trial-in-progress

Revumenib plus IC in newly diagnosed NPM1-mutated AML: REVEAL-ND NPM1 trial-in-progress

In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY,

Accelerating Discoveries: The Children's Brain Tumor Network

Accelerating Discoveries: The Children's Brain Tumor Network

Recent medical advances are revealing hidden clues about the underlying biology of pediatric cancers and are helping to rapidly ...

Actuate Therapeutics: targeting cancer on multiple fronts with elraglusib

Actuate Therapeutics: targeting cancer on multiple fronts with elraglusib

Actuate Therapeutics' new mechanism-of-action animation easily explains how elraglusib, a novel GSK-3β inhibitor, is designed ...

Episode 7: PD-L1 Testing in Head & Neck Cancer - Current Practice and Clinical Impact

Episode 7: PD-L1 Testing in Head & Neck Cancer - Current Practice and Clinical Impact

In Episode 7 of Agilent's Dialogues in CDx, we turn our focus to recent advances in head and neck cancers, a field marked by ...

Phase II Trial in Glioblastoma with ONC201, a First in Class DRD2 Antagonist

Phase II Trial in Glioblastoma with ONC201, a First in Class DRD2 Antagonist

Dr. Arrillaga is a neuro-oncologist at the Massachusetts General Hospital. She served as clinical director of the Pappas Center for ...

Gilian Crowther, Director of Research talks about ArminLabs testing

Gilian Crowther, Director of Research talks about ArminLabs testing

An

ACT’s Phase 1/2 Clinical Trials Show Safety & Signs of Visual Improvement – Published in The Lancet

ACT’s Phase 1/2 Clinical Trials Show Safety & Signs of Visual Improvement – Published in The Lancet

ACT publishes phase 1/2 clinical trial data showing safety and signs of visual improvement of RPE cells for the treatment of ...

Introducing the new linear accelerator at Novant Health Cancer Institute – Kernersville.

Introducing the new linear accelerator at Novant Health Cancer Institute – Kernersville.

When radiation therapy is recommended, patients will now have access to the recently installed TrueBeam linear accelerator at ...